Evidence map›Paper›PMID 36366326›Full record

ArticleVaccines2022

COVID-19 Breakthrough Infections among Patients Aged ≥65 Years in Serbia: Morbidity and Mortality Overview.

Monika P Bajči, Dajana F Lendak, Mioljub Ristić, Maja M Drljača, Snežana Brkić, Vesna Turkulov, Vladimir Petrović

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Vaccines, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.1field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 11 citations in OpenAlex.

  1. Trial
  2. Observational
  3. Review
  4. Article
  5. Review
  6. Review
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Monika P BajčiDepartment of Infectious Diseases, Faculty of Medicine, University of Novi Sad, Hajduk Veljkova 3, 21112 Novi Sad, Serbia.
Dajana F LendakDepartment of Infectious Diseases, Faculty of Medicine, University of Novi Sad, Hajduk Veljkova 3, 21112 Novi Sad, Serbia.
Mioljub RistićDepartment of Epidemiology, Faculty of Medicine, University of Novi Sad, Hajduk Veljkova 3, 21112 Novi Sad, Serbia.ORCID 0000-0002-6923-189X
Maja M DrljačaDepartment of Infectious Diseases, Faculty of Medicine, University of Novi Sad, Hajduk Veljkova 3, 21112 Novi Sad, Serbia.
Snežana BrkićDepartment of Infectious Diseases, Faculty of Medicine, University of Novi Sad, Hajduk Veljkova 3, 21112 Novi Sad, Serbia.
Vesna TurkulovDepartment of Infectious Diseases, Faculty of Medicine, University of Novi Sad, Hajduk Veljkova 3, 21112 Novi Sad, Serbia.
Vladimir PetrovićDepartment of Epidemiology, Faculty of Medicine, University of Novi Sad, Hajduk Veljkova 3, 21112 Novi Sad, Serbia.
University of Novi Sad · RS

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundVaccines against severe acute respiratory syndrome coronavirus 2 have shown effectiveness in the prevention of COVID-19. Breakthrough infections occur, and age has been shown to be one of the dominant risk factors for poorer outcome. This research focuses on characteristics of breakthrough infections in older adults.

methodsThis retrospective study was conducted for four months (March−June 2021) in the autonomous province of Vojvodina in Serbia on 11,372 patients using reverse-transcription polymerase chain reaction or antigen-detection rapid diagnostic tests verifying COVID-19 in those aged ≥65 years. Demographics, comorbidities, disease severity, and final outcomes were evaluated in fully vaccinated compared to unvaccinated individuals. Individuals were divided into younger-old (65−74 years) and older-old (≥75 years) age groups and differences between those groups were further evaluated. Binary logistic regression was performed to identify independent predictors of poor outcome.

resultsBy the end of the research, 51.3% of the population of APV 65−74 years, as well as 46.2% of those older than 74 years, were vaccinated. From the acquired sample, 17.4% had breakthrough infection. Asymptomatic forms were higher in both age groups of vaccinated vs. unvaccinated (3.9%—younger-old, 6.3%—older-old vs. 2.9%—younger-old, 3.9%—older-old). The same results were registered with mild symptoms (82.1%—younger-old, 68.1%—older-old vs. 76.3%—younger-old, 57.5%—older-old) (p < 0.001). The case fatality ratio of the vaccinated population was smaller than the unvaccinated population in both groups (3.1% vs. 7.9%—younger-old; 11.4% vs. 22.5%—older-old) (p < 0.001). The odds ratio for poor outcome in unvaccinated individuals was 2.3 (95% confidence interval, p < 0.001) for the total sample.

conclusionsAn increase in asymptomatic and mild forms, as well as decrease in severe or critical forms and poor outcomes, were noted in the vaccinated population. Choosing to avoid vaccination against SARS-CoV-2 may increase the chance of poor outcome in older individuals.

Indexed as

breakthrough infectionCOVID-19geriatric medicineolder adults

Identifiers

PMID36366326
PMCPMC9695717
OpenAlexW4307623786

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.